Atlas-backed biotech focused on Huntington's disease shuts down less than three years after launch

An Atlas-founded biotech quietly shut down this week, with the CEO posting only a short statement on LinkedIn to announce the move.

Triplet Therapeutics is no longer operational, chief exec Nessan Bermingham said on the social media site Tuesday, less than three years after it launched. In December 2019, Triplet debuted with a $59 million Series A, nabbing cash from Atlas, MPM Capital and Pfizer Ventures in an effort to develop antisense drugs for Huntington’s disease.